LakeShore Biopharma Co., Ltd (OTCPK: LSBCF; OTCPK: LSBWF) announced today that its shareholders have voted to approve the merger agreement that will take the company private. At an extraordinary general meeting held on June 19, 2026, approximately 92.3% of the company's outstanding ordinary shares voted, with 86.2% of votes cast in favor of the merger.
The merger, originally announced on November 4, 2025, and amended on April 29, 2026, involves LakeShore Biopharma, Oceanpine Skyline Inc. (Parent), and Oceanpine Merger Sub Inc. (Merger Sub). Under the terms, Merger Sub will merge with and into LakeShore Biopharma, which will continue as the surviving entity and become a wholly owned subsidiary of Parent. Following the merger, LakeShore's shares and warrants will be delisted from the OTC Pink tier of the OTC Markets and deregistered under Section 12 of the Securities Exchange Act of 1934.
For business leaders in the biopharmaceutical and technology sectors, this move underscores a trend of public biotech companies seeking private ownership to reduce regulatory burdens and focus on long-term R&D without quarterly earnings pressure. LakeShore Biopharma, formerly known as YS Biopharma, specializes in vaccines and therapeutic biologics for infectious diseases and cancer, leveraging its proprietary PIKA® immunomodulating technology platform. The company operates in China, Singapore, and the Philippines, targeting diseases such as rabies, hepatitis B, and influenza.
The merger's completion is subject to customary conditions, which the company expects to satisfy in due course. Once finalized, LakeShore will no longer be subject to SEC reporting requirements, potentially allowing greater operational flexibility. However, investors should note that forward-looking statements in the press release, available at https://investors.lakeshorebio.com/, highlight risks including possible termination of the merger agreement, financing availability, and market conditions.
This development is significant for the industry as it reflects the ongoing consolidation and strategic realignment in the biopharmaceutical space, particularly among smaller players seeking stability away from public markets. For leaders in business and technology, the move signals that private equity and strategic investors continue to see value in vaccine and biologic platforms, even as public market volatility persists.
